Baker Bros. Advisors LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Baker Bros. Advisors LP disclosed 93 US equity positions worth $9.6bn in its Q3 2024 13F filing. The largest position was ONC at 24.6% of the reported book, followed by INCY and ACAD.
What did Baker Bros. Advisors LP own in Q3 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | ONC BeiGene, Ltd. | Healthcare | 24.6% | $2.4bn | 10,568,897 | – | |
| 2 | INCY Incyte Corporation | Healthcare | 21.1% | $2.0bn | 30,739,020 | – | |
| 3 | ACAD ACADIA Pharmaceuticals Inc. | Healthcare | 6.8% | $659.5m | 42,877,916 | – | |
| 4 | SMMT Summit Therapeutics Inc. | Healthcare | 5.5% | $534.9m | 24,424,865 | – | |
| 5 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 4.3% | $419.0m | 1,974,590 | – | |
| 6 | RVMD Revolution Medicines, Inc. | Healthcare | 3.6% | $343.3m | 7,569,090 | – | |
| 7 | RYTM Rhythm Pharmaceuticals, Inc. | Healthcare | 3.5% | $335.2m | 6,398,366 | – | |
| 8 | INSM Insmed Incorporated | Healthcare | 3.3% | $322.4m | 4,415,918 | – | |
| 9 | KYMR Kymera Therapeutics, Inc. | Healthcare | 2.9% | $283.8m | 5,995,929 | – | |
| 10 | BCYC Bicycle Therapeutics plc | Healthcare | 2.2% | $212.7m | 9,399,960 | – | |
| 11 | EWTX Edgewise Therapeutics, Inc. | 1.6% | $155.9m | 5,840,059 | – | ||
| 12 | REPL Replimune Group, Inc. | Healthcare | 1.3% | $121.1m | 11,045,336 | – | |
| 13 | ALKS Alkermes plc | Healthcare | 1.2% | $117.0m | 4,181,751 | – | |
| 14 | DNLI Denali Therapeutics Inc. | Healthcare | 1.1% | $108.7m | 3,731,695 | – | |
| 15 | INSM Insmed Incorporated | 1.0% | $98.3m | 42,850,000 | – | ||
| 16 | RARE Ultragenyx Pharmaceutical Inc. | Healthcare | 0.9% | $87.6m | 1,576,114 | – | |
| 17 | NRIX Nurix Therapeutics, Inc. | Healthcare | 0.9% | $87.2m | 3,882,125 | – | |
| 18 | TRDA Entrada Therapeutics, Inc. | 0.8% | $77.8m | 4,865,819 | – | ||
| 19 | IMTX Immatics N.V. | Healthcare | 0.8% | $73.5m | 6,443,398 | – | |
| 20 | ABCL AbCellera Biologics Inc. | Healthcare | 0.7% | $71.6m | 27,525,640 | – | |
| 21 | Kiniksa Pharmaceuticals International, plc | 0.7% | $70.4m | 2,818,323 | – | ||
| 22 | 1K0 IGM Biosciences, Inc. | 0.7% | $67.7m | 4,092,310 | – | ||
| 23 | ARGX argenx SE | Healthcare | 0.6% | $60.7m | 111,904 | – | |
| 24 | STOK Stoke Therapeutics, Inc. | Healthcare | 0.6% | $53.7m | 4,368,443 | – | |
| 25 | IMCR Immunocore Holdings plc | Healthcare | 0.5% | $47.2m | 1,515,318 | – | |
| 26 | KOD Kodiak Sciences Inc. | Healthcare | 0.5% | $45.2m | 17,310,490 | – | |
| 27 | SERA Sera Prognostics, Inc. | 0.4% | $42.4m | 5,434,399 | – | ||
| 28 | CRSP CRISPR Therapeutics AG | Healthcare | 0.4% | $39.6m | 843,075 | – | |
| 29 | XENE Xenon Pharmaceuticals Inc. | Healthcare | 0.4% | $39.1m | 993,679 | – | |
| 30 | IMVT Immunovant, Inc. | Healthcare | 0.4% | $34.9m | 1,225,410 | – | |
| 31 | CERS Cerus Corporation | Healthcare | 0.4% | $33.9m | 19,477,339 | – | |
| 32 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 0.3% | $33.6m | 1,062,123 | – | |
| 33 | ROIV Roivant Sciences Ltd. | Healthcare | 0.3% | $32.3m | 2,798,716 | – | |
| 34 | Akero Therapeutics, Inc. | 0.3% | $31.5m | 1,097,082 | – | ||
| 35 | KRYS Krystal Biotech, Inc. | Healthcare | 0.3% | $30.9m | 169,934 | – | |
| 36 | CELC Celcuity Inc. | Healthcare | 0.3% | $28.0m | 1,874,978 | – | |
| 37 | GLUE Monte Rosa Therapeutics, Inc. | 0.3% | $26.1m | 4,916,095 | – | ||
| 38 | DYN Dyne Therapeutics, Inc. | Healthcare | 0.3% | $24.1m | 672,096 | – | |
| 39 | BMEA Biomea Fusion, Inc. | 0.2% | $21.3m | 2,108,949 | – | ||
| 40 | BCAX Bicara Therapeutics Inc. | 0.2% | $21.2m | 833,333 | – | ||
| 41 | PRLD Prelude Therapeutics Inc. | 0.2% | $21.0m | 10,123,824 | – | ||
| 42 | CNTA Centessa Pharmaceuticals plc | 0.2% | $19.6m | 1,227,178 | – | ||
| 43 | NGNE Neurogene Inc. | 0.2% | $19.1m | 456,015 | – | ||
| 44 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 0.2% | $18.6m | 323,105 | – | |
| 45 | ALMS Alumis Inc. | 0.2% | $16.7m | 1,562,500 | – | ||
| 46 | Merus N.V. | 0.2% | $15.0m | 300,000 | – | ||
| 47 | TCRX TScan Therapeutics, Inc. | 0.1% | $13.9m | 2,784,792 | – | ||
| 48 | NMRA Neumora Therapeutics, Inc. | Healthcare | 0.1% | $13.7m | 1,034,600 | – | |
| 49 | XNCR Xencor, Inc. | Healthcare | 0.1% | $13.5m | 670,431 | – | |
| 50 | TSVT* 2seventy bio, Inc. | 0.1% | $11.8m | 2,497,526 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.